Dermira (DERM) Downgraded by BidaskClub

Dermira (NASDAQ:DERM) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Monday, February 5th.

A number of other analysts have also recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $45.00 price objective on shares of Dermira in a research report on Monday, November 6th. Guggenheim assumed coverage on Dermira in a research note on Tuesday, December 5th. They set a “buy” rating for the company. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Mizuho reduced their price objective on Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Finally, Leerink Swann lifted their price target on Dermira from $42.00 to $48.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Dermira currently has an average rating of “Hold” and an average price target of $42.17.

Shares of Dermira (DERM) opened at $26.69 on Monday. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $1,145.62, a price-to-earnings ratio of -4.28 and a beta of 0.75. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75.

In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total value of $82,020.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,258 shares of company stock worth $935,153. Insiders own 13.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP raised its position in Dermira by 75.4% in the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares during the period. Aperio Group LLC purchased a new stake in shares of Dermira during the fourth quarter worth $213,000. Two Sigma Advisers LP purchased a new stake in shares of Dermira during the fourth quarter worth $222,000. SG Americas Securities LLC increased its position in shares of Dermira by 47.7% during the third quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 2,627 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Dermira by 40.9% during the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 2,803 shares during the period. 95.27% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/22/dermira-derm-rating-lowered-to-hold-at-bidaskclub.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply